查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
胜肽市場 - 全球市場規模、佔有率、趨勢分析、機會、預測報告（2019-2029）
市場調查報告書
商品編碼
1391804

胜肽市場 - 全球市場規模、佔有率、趨勢分析、機會、預測報告（2019-2029）

Antimicrobial Peptides Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product ; By Ailments ; By Distribution Channel ; By Route of Administration ; By End Use ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 200 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球胜肽市場規模以5.54%的年複合成長率穩定成長，到2029年將達到75.6億美元。

由於抗菌素抗藥性、感染疾病的流行、醫學和生物技術應用的擴大以及胜肽合成技術的進步，對替代抗生素的需求增加，全球胜肽市場正在蓬勃發展。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，2022 年全球胜肽市場規模將達到 54.7 億美元。 BlueWeave預測，在2023-2029年的預測期內，全球胜肽市場規模將以5.54%的年複合成長率成長，並於2029年達到75.6億美元。抗藥性疾病的增加增加了對替代治療藥物的需求，例如胜肽，這些藥物對抗藥性細菌表現出良好的效果，是推動全球胜肽市場成長的關鍵因素之一。此外，胜肽生產和合成方法的改進降低了生產成本並使其更容易獲得。研發成本的增加也導致了新的胜肽類藥物的誕生，擴大了市場。隨著人們對胜肽在一系列醫療和非醫療應用（包括食品保鮮和農業）中的益處的了解的增加，進一步推動了市場的擴張。

該報告的詳細分析提供了有關全球胜肽市場的成長潛力、未來趨勢和統計數據的資訊。它還重點關注推動市場總規模預測的因素。該報告致力於提供全球胜肽市場的最新技術趨勢以及產業見解，幫助決策者做出策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第2章 執行摘要

第3章 全球胜肽市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 感染疾病增加
      • 擴大使用胜肽作為治療劑
      • 抗菌藥物抗藥性發生率上升
    • 抑制因素
      • 開發成本高
      • 穩定性和配方問題
    • 機會
      • 技術進步
      • 中心導管相關血流感染疾病的發生率增加
    • 任務
      • 監管挑戰
      • 市場認知度有限
  • 科技進步/最新發展
  • 法律規範
  • 波特五力分析

第4章 全球胜肽市場概況

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 依產品
      • 植物
      • 細菌
      • 動物
      • 昆蟲
    • 按疾病分類
    • 按配銷通路
    • 依給藥途徑
      • 局部的
      • 皮下的
      • 靜脈
    • 按最終用途
      • 製藥與醫療保健
      • 農業工業
      • 生物工程
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東和非洲

第5章 北美胜肽市場

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 依產品
    • 按疾病分類
    • 按配銷通路
    • 依給藥途徑
    • 按最終用途
    • 按國家/地區
      • 美國
      • 加拿大

第6章 歐洲胜肽市場

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 依產品
    • 按疾病分類
    • 按配銷通路
    • 依給藥途徑
    • 按最終用途
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第7章 亞太胜肽市場

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 依產品
    • 按疾病分類
    • 按配銷通路
    • 依給藥途徑
    • 按最終用途
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 其他亞太地區

第8章 拉丁美洲胜肽市場

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 依產品
    • 按疾病分類
    • 按配銷通路
    • 依給藥途徑
    • 按最終用途
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第9章 中東及非洲胜肽市場

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 依產品
    • 按疾病分類
    • 按配銷通路
    • 依給藥途徑
    • 按最終用途
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東/非洲

第10章 競爭形勢

  • 主要企業及其產品列表
  • 全球胜肽企業市場佔有率分析（2022年）
  • 透過管理參數進行競爭基準化分析
  • 主要策略發展（合併、收購、合作夥伴關係等）

第11章COVID-19對全球胜肽市場的影響

第12章公司簡介（公司簡介、財務矩陣、競爭形勢、關鍵人才、主要競爭、聯絡地址、策略展望、SWOT分析）

  • Eli Lilly and Company
  • Pfizer Inc.
  • GSK Group of Companies（US）
  • Novartis AG
  • EnBiotix Inc.
  • Johnson &Johnson Private Limited
  • Merck &Co., Inc.
  • Alexion Pharmaceuticals, Inc.
  • Melinta Therapeutics, LLC
  • Vertex Pharmaceuticals Incorporated
  • AnaSpec
  • AMP Biotech
  • Phoenix Biotechnology Inc.
  • Novabiotics
  • Ontores Biotechnologies Inc.
  • 其他主要企業

第13章主要戰略建議

第14章調查方法

簡介目錄
Product Code: BWC23959

Global Antimicrobial Peptides Market Size Set to Grow at Steady CAGR of 5.54% Reaching USD 7.56 Billion by 2029.

Global antimicrobial peptides market is flourishing due to an increasing demand for alternative antibiotics due to antimicrobial resistance, the rising prevalence of infectious diseases, expanding applications in pharmaceuticals and biotechnology, and advancements in peptide synthesis technologies.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global antimicrobial peptides market size at USD 5.47 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global antimicrobial peptides market size to grow at a CAGR of 5.54% reaching a value of USD 7.56 billion by 2029. The rising incidence of drug-resistant illnesses spurred the desire for alternative therapeutics, such as antimicrobial peptides, which exhibit promising efficacy against resistant bacteria and are one of the major reasons driving the growth of the global antimicrobial peptides market. Also, improvements in peptide manufacturing and synthesis methods lowered production costs and increased accessibility. Increasing research and development spending also resulted in the creation of new peptide-based medicines, which expanded the market. The market expansion is further fueled by growing knowledge of the advantages of antimicrobial peptides in a range of medical and non-medical uses, including food preservation and agriculture.

Antimicrobial Peptides - Overview

Antimicrobial peptides (AMPs) are naturally occurring tiny compounds present in a wide range of organisms, including people, plants, and animals. They are essential in innate immunity, as they protect against microbial infections. The antimicrobial activity of AMPs is broad-spectrum, targeting bacteria, fungi, viruses, and even some parasites. Their distinct method of action involves breaking microbial membranes, resulting in cell death, and they are resistant to resistance formation. AMPs have sparked attention in the fight against antibiotic-resistant bacteria and other infectious disorders due to their potential therapeutic applications. However, there are still issues in optimizing their stability and bioavailability for therapeutic usage, necessitating continuous study.

Impact of COVID-19 on Global Antimicrobial Peptides Market

The COVID-19 pandemic significantly impacted the global antimicrobial peptides market, causing a dynamic shift in demand and supply chains. With heightened awareness of infection prevention and treatment, the market witnessed accelerated research and development, driving innovation and adoption of antimicrobial peptides as potential therapeutic agents against the virus. However, disruptions in manufacturing, logistical challenges, and resource reallocation to combat the pandemic resulted in temporary setbacks for some market players. Despite these challenges, the pandemic underscored the importance of antimicrobial peptides, prompting increased investments and collaborations for developing robust antimicrobial solutions, and fostering long-term growth prospects for the market.

Global Antimicrobial Peptides Market - By Ailments

By ailments, the global antimicrobial peptides market is divided into Pneumonia, Hepatitis, Bacterial infections, and HIV segments. These segments represent distinct areas of application for antimicrobial peptides, which are naturally occurring molecules with potent antimicrobial properties. The market is driven by the increasing prevalence of infectious diseases and the growing demand for effective treatment options. Each segment presents unique challenges and opportunities, prompting pharmaceutical companies and researchers to explore and develop innovative peptide-based therapies to combat these specific diseases. This segmentation enables targeted approaches and tailored solutions to address the diverse healthcare needs associated with these infectious conditions.

Competitive Landscape

Global antimicrobial peptides market is fiercely competitive. Major companies in the market include Eli Lilly and Company, Pfizer Inc., GSK Group of Companies (U.S.), Novartis AG, EnBiotix Inc., Johnson & Johnson Private Limited, Merck & Co., Inc., Alexion Pharmaceuticals, Inc., Melinta Therapeutics, LLC, Vertex Pharmaceuticals Incorporated, AnaSpec, AMP Biotech, Phoenix Biotechnology Inc., Novabiotics, and Ontores Biotechnologies Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in global antimicrobial peptides market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Antimicrobial Peptides Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antimicrobial Peptides Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Antimicrobial Peptides Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rise in infectious diseases
      • 3.2.1.2. Increasing usage of antimicrobial peptides as therapeutic agents
      • 3.2.1.3. Rising incidence of antimicrobial resistance
    • 3.2.2. Restraints
      • 3.2.2.1. High development costs
      • 3.2.2.2. Stability and formulation issues:
    • 3.2.3. Opportunities
      • 3.2.3.1. Technological advancements
      • 3.2.3.2. Rising incidence of central line-associated bloodstream infections
    • 3.2.4. Challenges
      • 3.2.4.1. Regulatory challenges
      • 3.2.4.2. Limited market awareness
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Antimicrobial Peptides Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Plant
      • 4.2.1.2. Bacterial
      • 4.2.1.3. Animal
      • 4.2.1.4. Insect
    • 4.2.2. By Ailments
      • 4.2.2.1.1. Pneumonia
      • 4.2.2.1.2. Hepatitis
      • 4.2.2.1.3. Bacterial infections
      • 4.2.2.1.4. HIV
    • 4.2.3. By Distribution Channel
      • 4.2.3.1.1. Hospital
      • 4.2.3.1.2. Research Institutes
      • 4.2.3.1.3. Specialty Clinic
      • 4.2.3.1.4. Pharmacies
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Topical
      • 4.2.4.2. Subcutaneous
      • 4.2.4.3. Intravenous
    • 4.2.5. By End Use
      • 4.2.5.1. Pharma and Healthcare
      • 4.2.5.2. Agriculture Industry
      • 4.2.5.3. Biological Engineering
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia Pacific (APAC)
      • 4.2.6.4. Latin America (LATAM)
      • 4.2.6.5. Middle East and Africa (MEA)

5. North America Antimicrobial Peptides Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
    • 5.2.2. By Ailments
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Route of Administration
    • 5.2.5. By End Use
    • 5.2.6. By Country
      • 5.2.6.1. United States
      • 5.2.6.1.1. By Product
      • 5.2.6.1.2. By Ailments
      • 5.2.6.1.3. By Distribution Channel
      • 5.2.6.1.4. By Route of Administration
      • 5.2.6.1.5. By End Use
      • 5.2.6.2. Canada
      • 5.2.6.2.1. By Product
      • 5.2.6.2.2. By Ailments
      • 5.2.6.2.3. By Distribution Channel
      • 5.2.6.2.4. By Route of Administration
      • 5.2.6.2.5. By End Use

6. Europe Antimicrobial Peptides Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Ailments
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Route of Administration
    • 6.2.5. By End Use
    • 6.2.6. By Country
      • 6.2.6.1. Germany
      • 6.2.6.1.1. By Product
      • 6.2.6.1.2. By Ailments
      • 6.2.6.1.3. By Distribution Channel
      • 6.2.6.1.4. By Route of Administration
      • 6.2.6.1.5. By End Use
      • 6.2.6.2. United Kingdom
      • 6.2.6.2.1. By Product
      • 6.2.6.2.2. By Ailments
      • 6.2.6.2.3. By Distribution Channel
      • 6.2.6.2.4. By Route of Administration
      • 6.2.6.2.5. By End Use
      • 6.2.6.3. Italy
      • 6.2.6.3.1. By Product
      • 6.2.6.3.2. By Ailments
      • 6.2.6.3.3. By Distribution Channel
      • 6.2.6.3.4. By Route of Administration
      • 6.2.6.3.5. By End Use
      • 6.2.6.4. France
      • 6.2.6.4.1. By Product
      • 6.2.6.4.2. By Ailments
      • 6.2.6.4.3. By Distribution Channel
      • 6.2.6.4.4. By Route of Administration
      • 6.2.6.4.5. By End Use
      • 6.2.6.5. Spain
      • 6.2.6.5.1. By Product
      • 6.2.6.5.2. By Ailments
      • 6.2.6.5.3. By Distribution Channel
      • 6.2.6.5.4. By Route of Administration
      • 6.2.6.5.5. By End Use
      • 6.2.6.6. Belgium
      • 6.2.6.6.1. By Product
      • 6.2.6.6.2. By Ailments
      • 6.2.6.6.3. By Distribution Channel
      • 6.2.6.6.4. By Route of Administration
      • 6.2.6.6.5. By End Use
      • 6.2.6.7. Russia
      • 6.2.6.7.1. By Product
      • 6.2.6.7.2. By Ailments
      • 6.2.6.7.3. By Distribution Channel
      • 6.2.6.7.4. By Route of Administration
      • 6.2.6.7.5. By End Use
      • 6.2.6.8. The Netherlands
      • 6.2.6.8.1. By Product
      • 6.2.6.8.2. By Ailments
      • 6.2.6.8.3. By Distribution Channel
      • 6.2.6.8.4. By Route of Administration
      • 6.2.6.8.5. By End Use
      • 6.2.6.9. Rest of Europe
      • 6.2.6.9.1. By Product
      • 6.2.6.9.2. By Ailments
      • 6.2.6.9.3. By Distribution Channel
      • 6.2.6.9.4. By Route of Administration
      • 6.2.6.9.5. By End Use

7. Asia Pacific Antimicrobial Peptides Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Ailments
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Route of Administration
    • 7.2.5. By End Use
    • 7.2.6. By Country
      • 7.2.6.1. China
      • 7.2.6.1.1. By Product
      • 7.2.6.1.2. By Ailments
      • 7.2.6.1.3. By Distribution Channel
      • 7.2.6.1.4. By Route of Administration
      • 7.2.6.1.5. By End Use
      • 7.2.6.2. India
      • 7.2.6.2.1. By Product
      • 7.2.6.2.2. By Ailments
      • 7.2.6.2.3. By Distribution Channel
      • 7.2.6.2.4. By Route of Administration
      • 7.2.6.2.5. By End Use
      • 7.2.6.3. Japan
      • 7.2.6.3.1. By Product
      • 7.2.6.3.2. By Ailments
      • 7.2.6.3.3. By Distribution Channel
      • 7.2.6.3.4. By Route of Administration
      • 7.2.6.3.5. By End Use
      • 7.2.6.4. South Korea
      • 7.2.6.4.1. By Product
      • 7.2.6.4.2. By Ailments
      • 7.2.6.4.3. By Distribution Channel
      • 7.2.6.4.4. By Route of Administration
      • 7.2.6.4.5. By End Use
      • 7.2.6.5. Australia & New Zealand
      • 7.2.6.5.1. By Product
      • 7.2.6.5.2. By Ailments
      • 7.2.6.5.3. By Distribution Channel
      • 7.2.6.5.4. By Route of Administration
      • 7.2.6.5.5. By End Use
      • 7.2.6.6. Indonesia
      • 7.2.6.6.1. By Product
      • 7.2.6.6.2. By Ailments
      • 7.2.6.6.3. By Distribution Channel
      • 7.2.6.6.4. By Route of Administration
      • 7.2.6.6.5. By End Use
      • 7.2.6.7. Malaysia
      • 7.2.6.7.1. By Product
      • 7.2.6.7.2. By Ailments
      • 7.2.6.7.3. By Distribution Channel
      • 7.2.6.7.4. By Route of Administration
      • 7.2.6.7.5. By End Use
      • 7.2.6.8. Singapore
      • 7.2.6.8.1. By Product
      • 7.2.6.8.2. By Ailments
      • 7.2.6.8.3. By Distribution Channel
      • 7.2.6.8.4. By Route of Administration
      • 7.2.6.8.5. By End Use
      • 7.2.6.9. Vietnam
      • 7.2.6.9.1. By Product
      • 7.2.6.9.2. By Ailments
      • 7.2.6.9.3. By Distribution Channel
      • 7.2.6.9.4. By Route of Administration
      • 7.2.6.9.5. By End Use
      • 7.2.6.10. Rest of APAC
      • 7.2.6.10.1. By Product
      • 7.2.6.10.2. By Ailments
      • 7.2.6.10.3. By Distribution Channel
      • 7.2.6.10.4. By Route of Administration
      • 7.2.6.10.5. By End Use

8. Latin America Antimicrobial Peptides Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Ailments
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Route of Administration
    • 8.2.5. By End Use
    • 8.2.6. By Country
      • 8.2.6.1. Brazil
      • 8.2.6.1.1. By Product
      • 8.2.6.1.2. By Ailments
      • 8.2.6.1.3. By Distribution Channel
      • 8.2.6.1.4. By Route of Administration
      • 8.2.6.1.5. By End Use
      • 8.2.6.2. Mexico
      • 8.2.6.2.1. By Product
      • 8.2.6.2.2. By Ailments
      • 8.2.6.2.3. By Distribution Channel
      • 8.2.6.2.4. By Route of Administration
      • 8.2.6.2.5. By End Use
      • 8.2.6.3. Argentina
      • 8.2.6.3.1. By Product
      • 8.2.6.3.2. By Ailments
      • 8.2.6.3.3. By Distribution Channel
      • 8.2.6.3.4. By Route of Administration
      • 8.2.6.3.5. By End Use
      • 8.2.6.4. Peru
      • 8.2.6.4.1. By Product
      • 8.2.6.4.2. By Ailments
      • 8.2.6.4.3. By Distribution Channel
      • 8.2.6.4.4. By Route of Administration
      • 8.2.6.4.5. By End Use
      • 8.2.6.5. Rest of LATAM
      • 8.2.6.5.1. By Product
      • 8.2.6.5.2. By Ailments
      • 8.2.6.5.3. By Distribution Channel
      • 8.2.6.5.4. By Route of Administration
      • 8.2.6.5.5. By End Use

9. Middle East and Africa Antimicrobial Peptides Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Ailments
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Route of Administration
    • 9.2.5. By End Use
    • 9.2.6. By Country
      • 9.2.6.1. Saudi Arabia
      • 9.2.6.1.1. By Product
      • 9.2.6.1.2. By Ailments
      • 9.2.6.1.3. By Distribution Channel
      • 9.2.6.1.4. By Route of Administration
      • 9.2.6.1.5. By End Use
      • 9.2.6.2. UAE
      • 9.2.6.2.1. By Product
      • 9.2.6.2.2. By Ailments
      • 9.2.6.2.3. By Distribution Channel
      • 9.2.6.2.4. By Route of Administration
      • 9.2.6.2.5. By End Use
      • 9.2.6.3. Qatar
      • 9.2.6.3.1. By Product
      • 9.2.6.3.2. By Ailments
      • 9.2.6.3.3. By Distribution Channel
      • 9.2.6.3.4. By Route of Administration
      • 9.2.6.3.5. By End Use
      • 9.2.6.4. Kuwait
      • 9.2.6.4.1. By Product
      • 9.2.6.4.2. By Ailments
      • 9.2.6.4.3. By Distribution Channel
      • 9.2.6.4.4. By Route of Administration
      • 9.2.6.4.5. By End Use
      • 9.2.6.5. South Africa
      • 9.2.6.5.1. By Product
      • 9.2.6.5.2. By Ailments
      • 9.2.6.5.3. By Distribution Channel
      • 9.2.6.5.4. By Route of Administration
      • 9.2.6.5.5. By End Use
      • 9.2.6.6. Nigeria
      • 9.2.6.6.1. By Product
      • 9.2.6.6.2. By Ailments
      • 9.2.6.6.3. By Distribution Channel
      • 9.2.6.6.4. By Route of Administration
      • 9.2.6.6.5. By End Use
      • 9.2.6.7. Algeria
      • 9.2.6.7.1. By Product
      • 9.2.6.7.2. By Ailments
      • 9.2.6.7.3. By Distribution Channel
      • 9.2.6.7.4. By Route of Administration
      • 9.2.6.7.5. By End Use
      • 9.2.6.8. Rest of MEA
      • 9.2.6.8.1. By Product
      • 9.2.6.8.2. By Ailments
      • 9.2.6.8.3. By Distribution Channel
      • 9.2.6.8.4. By Route of Administration
      • 9.2.6.8.5. By End Use

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Antimicrobial Peptides Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of COVID-19 on Global Antimicrobial Peptides Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Eli Lilly and Company
  • 12.2. Pfizer Inc.
  • 12.3. GSK Group of Companies (U.S)
  • 12.4. Novartis AG
  • 12.5. EnBiotix Inc.
  • 12.6. Johnson & Johnson Private Limited
  • 12.7. Merck & Co., Inc.
  • 12.8. Alexion Pharmaceuticals, Inc.
  • 12.9. Melinta Therapeutics, LLC
  • 12.10. Vertex Pharmaceuticals Incorporated
  • 12.11. AnaSpec
  • 12.12. AMP Biotech
  • 12.13. Phoenix Biotechnology Inc.
  • 12.14. Novabiotics
  • 12.15. Ontores Biotechnologies Inc.
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations